The Australian Garvan Institute’s study links high CDK1 activity in estrogen‑receptor positive breast tumors with poor outcomes and potential resistance to CDK4/6 drugs.
Medicine
Stories tagged "Medicine", newest first.
Also in Medicine
Stories tagged "Medicine", newest first.
The Australian Garvan Institute’s study links high CDK1 activity in estrogen‑receptor positive breast tumors with poor outcomes and potential resistance to CDK4/6 drugs.
